Beyond condoms and vasectomy: What will it take to make male contraception a mainstream choice?

For decades, contraception has largely been treated as a woman's responsibility. From taking a daily pill to managing hormonal side effects or choosing an intrauterine device, women have had to navigate a range of options to prevent an unintended pregnancy. For men, the choices remain comparatively limited: condoms, which require consistent use, and vasectomy, a surgical procedure intended to provide permanent contraception.

However, reproductive medicine is beginning to explore alternatives that could give men a more active role in family planning. From hormonal gels to experimental non-hormonal pills, researchers are investigating ways to prevent pregnancy without permanently affecting fertility. The question is whether scientific progress alone will be enough to make male contraception a mainstream choice.

Why are the options still so limited?

Developing male contraception presents a different biological challenge. While many female contraceptives prevent ovulation, male methods must either suppress sperm production or prevent sperm from reaching or fertilising an egg.

The testes produce millions of sperm continuously, meaning a contraceptive must reliably prevent fertilisation despite this ongoing production. Hormonal approaches attempt to suppress sperm production, while non-hormonal candidates target specific processes involved in sperm development or movement.

Researchers are exploring daily hormonal gels and experimental oral medicines that could offer reversible contraception. Yet these approaches remain under investigation, and none has become an approved, routinely available alternative to condoms or vasectomy. Their effectiveness, long-term safety and reversibility must be established through clinical trials before widespread use can be considered.

Safety and reversibility will determine public confidence

A major consideration for any new male contraceptive will be whether it can prevent pregnancy reliably without compromising future fertility.

A gynaecologist would emphasise that men considering contraception need clear evidence about potential side effects, the duration of protection and how quickly fertility returns after discontinuing a method. Hormonal approaches must also be assessed for their effects on mood, sexual function, skin health and other aspects of wellbeing.

These concerns are not unique to male contraception. Women also experience side effects from certain contraceptive methods, although experiences vary considerably. The objective should not be to suggest that one sex should bear every medical risk, but to expand the choices available to both.

For a new method to gain acceptance, its benefits and risks must be communicated transparently, allowing individuals and couples to make informed decisions.

Can social attitudes change alongside the science?

Medical innovation is only one part of the challenge. In many households, contraception is still regarded as the woman's responsibility, even when both partners wish to avoid pregnancy.

Some men may associate contraception with reduced masculinity, impaired sexual performance or permanent infertility. Others may hesitate because they are unfamiliar with emerging methods or uncertain about their reliability.

According to a gynaecologist, addressing these misconceptions will require better sexual health education, accessible counselling and open conversations between partners. Men must also be encouraged to participate in contraceptive consultations rather than leaving reproductive planning entirely to women.

What would make a new method practical for everyday life?

Convenience will matter. A contraceptive that requires complicated administration, frequent medical visits or difficult-to-manage side effects may struggle to gain acceptance, even if it proves effective.

Researchers and healthcare providers will need to consider affordability, ease of access, reliable supply and clear instructions for use. Clinical trials should also examine whether men can use a method consistently in real-world conditions, rather than simply demonstrating that it works under controlled circumstances.

Investment will be equally important. Developing a contraceptive requires substantial research, safety monitoring and large clinical trials. Sustained funding from research institutions, governments and pharmaceutical companies will be necessary to move promising candidates from laboratories into clinical practice.

A shared responsibility, not a replacement for women's choices

The arrival of effective male contraception would not make existing female methods unnecessary. Instead, it could give couples greater flexibility, particularly when a woman experiences side effects or prefers not to use a particular method.

Condoms would also remain important because most other contraceptive methods do not protect against sexually transmitted infections.

Ultimately, making male contraception mainstream will require more than a successful pill or gel. It will depend on reliable science, transparent safety evidence, affordable access and a cultural shift towards shared reproductive responsibility. The real measure of progress will be whether men have meaningful, medically sound choices—and whether couples can decide together how to prevent an unintended pregnancy.

The author is a senior consultant in Obstetrics & Gynaecology at Rosewalk by Rainbow Hospitals. 

 

The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.